Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy
Introduction: Standard treatment with cyclophosphamide (CP) or rituximab (RTX) is suboptimal. We adapted and used the low-dose regimen used in vasculitis (RTX 2 × 1000 mg, CP 1.5 mg/kg/d × 8 weeks, and prednisone [i.v. 2 × 1 g + 3 weeks oral starting at 1 mg/kg]). Methods: High-risk, anti-PLA2R anti...
Saved in:
| Main Authors: | Coralien H. Vink, Jack F.M. Wetzels, Anne-Els van de Logt |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924019211 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recurrence of Phospholipase A2 Receptor–Associated Membranous Nephropathy in the Absence of Serum Anti-Phospholipase A2 Receptor Antibodies Reappearance
by: Ilias Bensouna, et al.
Published: (2025-03-01) -
Safety and efficacy of sirolimus combined with cyclosporine in primary membranous nephropathy: a randomized controlled trial
by: Fang Wang, et al.
Published: (2025-05-01) -
Impact of Time-To-Treatment on Outcomes in Autoimmune Membranous Nephropathy
by: Patrick Hamilton, et al.
Published: (2025-06-01) -
Case Report: Subcutaneous ofatumumab for patients with immunosuppressant-dependent or ineffective primary membranous nephropathy
by: Jie Chen, et al.
Published: (2025-06-01) -
Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation
by: Marion Cremoni, et al.
Published: (2024-12-01)